Nilotinib Stada (Nilotinib)

Nilotinib acts on the BCR‑ABL tyrosine kinase pathway, providing targeted therapy for chronic myeloid leukemia.

• Chronic phase CML: reduces leukemic cell proliferation and achieves hematologic and cytogenetic responses.
• Accelerated phase CML: helps control disease progression and improves survival outcomes.
• Blast crisis CML: offers disease control when combined with other antileukemic agents.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, a fusion protein that drives uncontrolled proliferation of leukemic cells. By binding to the ATP‑binding site of the kinase, it blocks downstream signaling pathways such as RAS‑RAF‑MEK‑ERK and PI3K‑AKT, leading to reduced cell growth and induction of apoptosis in malignant clones.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools, often transient.
• Rash: skin erythema or pruritus.
• Headache: mild to moderate intensity.
• Fatigue: generalized tiredness.
• Myalgia: muscle aches or soreness.

Serious or Rare Side Effects

• QT interval prolongation: may predispose to ventricular arrhythmias.
• Pancreatitis: abdominal pain with elevated enzymes.
• Hepatic toxicity: elevated transaminases or bilirubin.
• Severe neutropenia: marked reduction in white blood cells.
• Severe thrombocytopenia: low platelet counts increasing bleeding risk.
• Stevens‑Johnson syndrome: severe skin and mucosal reactions.

Nilotinib requires careful monitoring and patient education to minimize risks.

• Cardiac monitoring: obtain baseline ECG and repeat periodically due to QT prolongation risk.
• Liver function: assess hepatic enzymes before initiation and during therapy.
• Blood counts: monitor complete blood count regularly for neutropenia or thrombocytopenia.
• Drug interactions: avoid concomitant strong CYP3A4 inhibitors or QT‑prolonging agents.
• Pregnancy and lactation: contraindicated; discuss contraception with patients of child‑bearing potential.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Nilotinib interacts with several drug classes that can alter its exposure or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase nilotinib plasma levels, raising toxicity risk.
• QT‑prolonging agents (e.g., amiodarone, sotalol): additive effect on cardiac repolarization.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce nilotinib exposure, compromising efficacy.

Moderate Interactions (Monitor Closely)

• Antacids, H2‑blockers, proton‑pump inhibitors: may decrease nilotinib absorption; separate dosing by at least 2 hours.
• Warfarin: nilotinib can increase INR; monitor coagulation parameters.
• Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): risk of elevated statin levels; consider dose adjustment or alternative lipid‑lowering therapy.